New GSMA Report Highlights Integral Role of Mobile IoT Networks in 5G Future
The GSMA today issued a new report, ‘NB-IoT and LTE-M in the 5G context’, highlighting the integral role that licensed Mobile IoT networks, such as NB-IoT and LTE-M, will play in the 5G future and, in particular, the development of ‘massive IoT’. Massive IoT is one of three principle 5G use cases, alongside critical communications and enhanced broadband, that will enable developments such as smart cities and industrial automation. NB-IoT and LTE-M will be fundamental to the development of massive IoT and in supporting and complementing 5G’s myriad use cases and applications. Leading operators including AT&T, Deutsche Telekom, KDDI, Orange and Vodafone are committed to deploying these networks as part of their future 5G massive IoT strategies.
“While people often associate 5G with super-fast mobile broadband speeds, it will also serve a variety of use cases often with diametrically opposed requirements such as low data rates and long battery life as with the case of Mobile IoT,” commented Alex Sinclair, Chief Technology Officer, GSMA. “Licensed NB-IoT and LTE-M networks are already delivering trusted connectivity today to millions of devices around the world, and these networks will continue to be a fundamental component of our 5G future ushering in an era of massive IoT.”
Mobile operators, in collaboration with global vendors and developers, are launching Mobile IoT networks today to support applications such as smart metering, smart logistics and smart environmental monitoring, but also as a core component of their long-term strategy and commitment to 5G IoT standards. Licensed Mobile IoT networks are standardised by 3GPP and are designed to support cellular IoT applications that are low cost, use low data rates, require long battery lives and often operate in remote and hard-to-reach locations such as industrial asset tracking, safety monitoring or water and gas metering. To date, 24 mobile operators have commercially launched 48 Mobile IoT networks worldwide across both NB-IoT and LTE-M technologies. According to GSMA Intelligence forecasts, by 2025 there will be 3.1 billion cellular IoT connections, including 1.8 billion licensed LPWA connections.
3GPP is set to complete Release 15 in June, which will include NB-IoT and LTE-M as 5G Mobile standards. 3GPP will also not include any additional LPWA requirements in its next release, meaning that NB-IoT and LTE-M will coexist with other 3GPP technologies and fulfil long-term 5G LPWA requirements. NB-IoT and LTE-M networks will deliver connectivity to billions of new devices and provide comprehensive IoT connectivity in the 5G era.
For more information on GSMA’s Mobile IoT Initiative and to download the report ‘NB-IoT and LTE-M in the 5G context’, please go to: https://www.gsma.com/iot/mobile-iot-5g-future/
“Low-Power Wide-Area networks hold the key to global deployment of IoT devices and applications that will only grow with 5G,” said Chris Penrose, President, Internet of Things Solutions, AT&T. “Our investment in Massive IoT in the U.S. and Mexico marks another step forward on our path to 5G with 3GPP standardised technology and licensed spectrum.”
“Deutsche Telekom fully supports GSMA’s statement of the integral role of Mobile IoT networks in the 5G future. Looking further, LPWA technologies such as NB-IoT have been paving the way for 5G and will be an important part of the 5G technologies – with its virtualised core networks already implemented at Deutsche Telekom, it is reality today for us,” said Dr. Ingo Hofacker, SVP, IOT, Deutsche Telekom.
“The GSMA report clarifies the ambiguity in the relationship between LPWA and 5G by highlighting that the existing LPWA 3GPP technologies are set to coexist with other 3GPP 5G technologies and fulfil longterm LPWA requirements. For the age of IoT and 5G, KDDI will establish Open Labs to facilitate the rapid development of innovative services in Tokyo in the summer of 2018,” said Keiichi Mori, Managing Executive Officer, GM, IoT Business Development Division.
Luke Ibbetson, Head of R&D for Vodafone Group and Chair of the GSMA NB-IoT Forum, said: “Vodafone pioneered the development of NB-IoT and already has networks in nine countries. We strongly believe that NB-IoT, the first 5G internet of things network, will be the foundation for a society where people and businesses are far more connected to and informed about the world around them.”
About the GSMA
The GSMA represents the interests of mobile operators worldwide, uniting nearly 800 operators with more than 300 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces industry-leading events such as Mobile World Congress, Mobile World Congress Shanghai, Mobile World Congress Americas and the Mobile 360 Series of conferences.
For more information, please visit the GSMA corporate website at www.gsma.com. Follow the GSMA on Twitter: @GSMA.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 14:00 | Tiedote
Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 11:10 | Tiedote
Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 18:13 | Tiedote
Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,
Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 17:00 | Tiedote
Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 16:41 | Tiedote
Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 15:00 | Tiedote
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme